mevastatin

mevastatin
IUPAC name	(3R,5R,6E)-7-[4-(6,7-Dimethoxy-4-methyl-3-oxo-1,2,3,4-tetrahydroquinolin-1-yl)-2-methoxyphenyl]-3,5-dihydroxyhept-6-enoic acid
CAS number	73573-88-3
PubChem	64715
DrugBank	DB09044
ChemSpiderID	58260

mevastatin. It is a naturally occurring statin and the first member of this class of cholesterol-lowering drugs to be discovered. Isolated from the fungus Penicillium citrinum by Akira Endo and colleagues at the Sankyo Co., Ltd. in Japan, it served as the foundational prototype for the development of all subsequent statins, including the widely used lovastatin and simvastatin. Although not marketed for therapeutic use due to adverse effects observed in early trials, its discovery was a pivotal moment in pharmacology and the treatment of cardiovascular disease.

History

The discovery of mevastatin in the early 1970s by Akira Endo was the result of a systematic screening program for microbial metabolites that could inhibit HMG-CoA reductase, a key enzyme in the mevalonate pathway. This work was conducted at the Sankyo Co., Ltd. research laboratories, inspired by the hypothesis that a compound from fungi could mimic the action of compactin. Initial in vitro and animal studies, including those on hens and dogs, demonstrated potent cholesterol-lowering effects. However, development was halted when toxicological studies, particularly on beagle dogs, revealed significant adverse effects, leading Sankyo to abandon clinical development. The compound's legacy was secured when researchers at Merck & Co. used it as a template to discover lovastatin from Aspergillus terreus, launching the modern statin era and profoundly impacting the management of atherosclerosis and coronary artery disease.

Medical uses

Mevastatin itself has never been approved for medical use in humans due to the toxicity profile identified during its early development. Its profound historical importance lies solely in its role as the pioneering compound that validated the therapeutic concept of HMG-CoA reductase inhibition. All subsequent statin drugs, which have become cornerstone therapies in clinical practice for preventing myocardial infarction and stroke, are direct chemical descendants of its structure. Its discovery proved the feasibility of safely lowering low-density lipoprotein (LDL) cholesterol through this mechanism, fundamentally altering the pharmacotherapy of dyslipidemia and influencing global treatment guidelines from organizations like the American Heart Association.

Mechanism of action

Mevastatin exerts its effect by competitively inhibiting the enzyme HMG-CoA reductase, which catalyzes the conversion of HMG-CoA to mevalonate in the hepatocyte cytoplasm. This step is the committed, rate-limiting step in the endogenous cholesterol synthesis pathway. By reducing the intracellular production of cholesterol, hepatocytes respond by increasing the expression of LDL receptors on their surface. This increased receptor activity enhances the clearance of LDL cholesterol and its precursor very-low-density lipoprotein (VLDL) from the bloodstream into the liver, thereby significantly lowering circulating levels of atherogenic lipoproteins. This mechanism, first elucidated with mevastatin, is shared by all members of the statin drug class.

Adverse effects

The adverse effects that halted the development of mevastatin were primarily observed in preclinical animal models, notably in studies involving beagle dogs. These effects included severe gastrointestinal toxicity, vacuolation of liver cells, and the development of lymphoma in some test subjects at high doses. The specific toxicity profile in dogs was not fully predictive of human response, as later statins were found to be well-tolerated, but it was sufficient for Sankyo to terminate the project. The experience underscored the critical importance of extensive toxicology screening in drug development and informed the safety evaluation of subsequent statins, which are associated with a different profile of side effects, such as myopathy and elevated liver enzymes.

Chemistry

Mevastatin is a polyketide compound with a complex structure featuring a hexahydronaphthalene ring system linked to a β-hydroxy-δ-lactone ring (in its inactive lactone form) or an open-chain dihydroxy heptanoic acid side chain (in its active hydroxyacid form). The active form closely resembles the intermediate HMG-CoA, allowing it to bind effectively to the HMG-CoA reductase enzyme. Key structural motifs include multiple methoxy groups and a methyl group on the decalin ring. Its molecular formula is C₂₃H₃₄O₅ for the lactone form. The molecule served as the essential chemical blueprint for medicinal chemistry efforts that produced analogs like lovastatin (which features an additional methyl group) and the fully synthetic atorvastatin.

Biosynthesis

In the producing fungus Penicillium citrinum, mevastatin is biosynthesized through a canonical polyketide synthase (PKS) pathway. A dedicated type I polyketide synthase, utilizing acetyl-CoA and malonyl-CoA as building blocks, assembles the polyketide chain that forms the core decalin moiety. This process involves a series of Claisen condensation reactions, ketoreduction, dehydration, and Diels-Alder cyclization steps. Post-PKS tailoring enzymes, including various oxidoreductases and methyltransferases, then modify the core structure, introducing the methoxy groups and forming the lactone ring. The genetics and enzymology of this pathway have been extensively studied, providing a model system for understanding fungal secondary metabolism and informing combinatorial biosynthesis approaches for novel compound discovery.

Category:Drugs